Xianyu Chen1, Chao He1, Dongdong Han2, Meirong Zhou1, Quan Wang3, Jinhui Tian4, Lun Li1, Feng Xu1, Enxiang Zhou1, Kehu Yang4. 1. Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. 2. Department of Urology, the Second Hospital of Lanzhou University, Lanzhou, China. 3. Department of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases, Xijing Hospital, Four Military Medical University, Xi'an, Shaanxi, China. 4. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Abstract
AIM: To review the predictive values of Ki-67 before neoadjuvant chemotherapy (NAC) for breast cancer patients. METHODS: PubMed and EMBASE were searched. Random-effect model meta-analysis was conducted using Revman software. RESULTS: High Ki-67 was associated with more pathological complete responses (pCRs) events (odds ratio: 3.10; 95% CI: 2.52-3.81; 53 studies, 10,848 patients) regardless of HR+, HER2+ and triple-negative breast cancer types, the definitions of pCR and cut-off points for Ki-67. Ki-67 could predict pCR in those who received anthracyclines plus taxanes, and anthracyclines only, and those from Asia and Europe. CONCLUSION: High Ki-67 before NAC was a predictor for pCR in neoadjuvant setting for breast cancer patients.
AIM: To review the predictive values of Ki-67 before neoadjuvant chemotherapy (NAC) for breast cancerpatients. METHODS: PubMed and EMBASE were searched. Random-effect model meta-analysis was conducted using Revman software. RESULTS: High Ki-67 was associated with more pathological complete responses (pCRs) events (odds ratio: 3.10; 95% CI: 2.52-3.81; 53 studies, 10,848 patients) regardless of HR+, HER2+ and triple-negative breast cancer types, the definitions of pCR and cut-off points for Ki-67. Ki-67 could predict pCR in those who received anthracyclines plus taxanes, and anthracyclines only, and those from Asia and Europe. CONCLUSION: High Ki-67 before NAC was a predictor for pCR in neoadjuvant setting for breast cancerpatients.
Authors: A Hendricks; F Gieseler; S Nazzal; J H Bräsen; R Lucius; B Sipos; J H Claasen; Th Becker; S Hinz; G Burmeister; C Schafmayer; C Schrader Journal: BMC Cancer Date: 2019-05-09 Impact factor: 4.430
Authors: Paul Gass; Michael P Lux; Claudia Rauh; Alexander Hein; Mayada R Bani; Cornelia Fiessler; Arndt Hartmann; Lothar Häberle; Jutta Pretscher; Ramona Erber; David L Wachter; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Peter A Fasching; Marius Wunderle Journal: BMC Cancer Date: 2018-10-29 Impact factor: 4.430